Searching for a few great drugs, BridgeBio bags $135M to back a fresh slate of R&D bets
BridgeBio is all about shots on goal.
The last time I wrote a story about the company in April, CEO Neil Kumar had just established his 9th subsidiary operation to explore a small molecule therapy for transthyretin (TTR) amyloidosis. And now it’s lined up $135 million — more than it’s ever raised before — to establish up to 10 more of these R&D efforts.
Significantly, KKR came back in to co-lead the round, joined by new investor Viking Global Investors. Existing investor Perceptive Advisors came back in, alongside a slate of new investors: AIG, Aisling Capital, Cormorant Capital and Janus Funds.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.